Federated Hermes
CUE icon

Federated Hermes’s Cue Biopharma CUE Stock Holding History

Federated Hermes’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-157
Closed -$23K – 2175
2022
Q1 		$23K Sell
157
-17
-10% -$3.6K ﹤0.01% 1815
2021
Q4 		$59K Buy
174
+46
+36% +$17.8K ﹤0.01% 1771
2021
Q3 		$56K Buy
128
+119
+1,322% +$41.5K ﹤0.01% 1854
2021
Q2 		$3K Sell
9
-5
-36% -$1.94K ﹤0.01% 2069
2021
Q1 		$5K Hold
14
– – ﹤0.01% 2064
2020
Q4 		$5K Sell
14
-3,220
-100% -$1.29M ﹤0.01% 2045
2020
Q3 		$1.46M Sell
3,234
-7,914
-71% -$4.56M ﹤0.01% 1097
2020
Q2 		$8.2M Buy
11,148
+8,248
+284% +$5.97M 0.02% 593
2020
Q1 		$1.23M Buy
2,900
+2,535
+695% +$1.23M ﹤0.01% 1050
2019
Q4 		$174K Buy
+365
New +$115K ﹤0.01% 1618

Other funds holding CUE

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Federated Hermes's CUE Position: Q2 2022 in Review

Federated Hermes sold out of Cue Biopharma (CUE) in Q2 2022, closing a stake of 157 shares — an estimated $23K sold.

Federated Hermes first reported a position in CUE in Q4 2019 and held it in 10 quarters. The position peaked at $8.2M in Q2 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2022.

  • Federated Hermes reported no remaining Cue Biopharma position as of Q2 2022 after selling out during the quarter.
  • Federated Hermes sold 157 Cue Biopharma shares in Q2 2022, an estimated $23K.
  • Federated Hermes first reported a position in Cue Biopharma in Q4 2019 and held it in 10 quarters.
  • Federated Hermes's Cue Biopharma position peaked at $8.2M in Q2 2020.
  • 75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2022.

Based on Federated Hermes's 13F filing for Q2 2022, filed 15 Aug 2022.